ORIGINAL ARTICLE
Assessment of CIP2A and ROCK-I expression and their prognostic value in breast cancer
1
Pathology Department, Faculty of Medicine, Minia University, Egypt
Submission date: 2019-08-27
Final revision date: 2020-01-30
Acceptance date: 2020-06-30
Publication date: 2020-07-21
Pol J Pathol 2020;71(2):87-98
KEYWORDS
TOPICS
ABSTRACT
Breast cancer is the most leading cause of cancer death in females worldwide. Identification of novel biomarkers for prognosis is required. Imunohistochemical evaluation of CIP2A and ROCK-1 expressions in 126 breast tissue specimens stratified as 21 ductal hyperplasias, 17 duct carcinoma in situ (DCIS) and 88 invasive carcinomas (56 invasive ductal carcinomas NST, 32 invasive lobular carcinomas) was studied. High CIP2A expression was detected in 48.9% of invasive carcinomas. CIP2A overexpression was significantly related to Nottingham prognostic index (NPI) (p = 0.011), stage (p = 0.01), ER negativity (p = 0.031), PR negativity (p = 0.048), and HER-2 positivity (p = 0.02). CIP2A was significantly overexpressed in triple-negative breast cancer (TNBC) (p = 0.004). ROCK-1 expression was detected in 54.5% of invasive carcinomas. Statistically significant associations were observed between ROCK-1 expression and NPI (p = 0.032), stage (p = 0.002), ER negativity (p = 0.012), PR negativity (p = 0.023), HER-2 positivity (p = 0.016), and TNBC subtype (p = 0.033). A positive association between CIP2A and ROCK-1 expressions (p < 0.0001) was documented. There was a significant association between shorter overall survival and high CIP2A and positive ROCK-1 expressions (p < 0.0001) and (p < 0.0001). CIP2A and ROCK-1 expressions could be used as markers for the poor prognosis of breast cancer.
REFERENCES (52)
1.
Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin 2018; 68: 394-424.
2.
Ibrahim AS, Khaled HM, Mikhail NH, et al. Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol 2014; 2014: ID 437971.
3.
Greenlee RT, Mukesh BN, Onitilo AA, Engel J. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res 2009; 7: 4-13.
4.
Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83: 803-819.
5.
Bast RC, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 2001; 19: 1865-1878.
6.
Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005; 65: 9603-9606.
7.
Marotti JD, de Abreu FB, Wells WA, Tsongalis GJ. Triple-Negative Breast Cancer, Next-Generation Sequencing for Target Identification. Am J Pathol 2017; 187: 2133-2138.
8.
Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 2009; 15: 454-460.
9.
Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-160.
10.
Khanna A, Pimanda JE, Westermarck J. Cancerous Inhibitor of Protein Phosphatase 2A, an Emerging Human Oncoprotein and a Potential Cancer Therapy Target. Cancer Res 2013; 73: 6548-6553.
11.
Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62.
12.
Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol 2006; 26: 2832-2844.
13.
Lucas CM, Harris RJ, Giannoudis A, et al. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloidleukemia is a critical determinant of disease progression. Blood 2011; 117: 6660-6668.
14.
Pang X, Fu X, Chen S, et al. Overexpression of CIP2A promotes bladder cancer progression by regulating EMT. Clin Transl Oncol 2016; 18: 289-295.
15.
Cha G, Xu J, Xu X, et al. High expression of CIP2A protein is associated with tumor aggressiveness in stage I-III NSCLC and correlates with poor prognosis. Onco Targets Ther 2017; 10: 5907-5914.
16.
Liu X, Cao W, Qin S, et al. Overexpression of CIP2A is associated with poorprognosis in multiplemyeloma. Signal Transduct Target Ther 2017; 2: 17013.
17.
Yu N, Zhang T, Zhao D, et al. CIP2A is overexpressed in human endometrioid adenocarcinoma and regulates cell proliferation, invasion and apoptosis. Pathol Res Pract 2018; 214: 233-239.
18.
Baldacchino S, Wastall LM, Saliba C, et al. CIP2A expression predicts recurrences of tamoxifen-treated breast cancer. Tumour Biol 2017; 39: 1010428317722064.
19.
Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 2010; 10: 397-419.
20.
Skarp KP, Vartiainen MK. Actin on DNA-An ancient and dynamic relationship. Cytoskeleton 2010; 67: 487-495.
21.
Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15: 2208-2216.
22.
Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases 2014; 5: e29846.
23.
Blumenstein L, Ahmadian MR. Models of the cooperative mechanism for Rho effector recognition: implications for RhoA-mediated effector activation. J Biol Chem 2004; 279: 53419-53426.
24.
Benitah SA, Valeron PF, van Aelst L, et al. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004; 1705: 121-132.
25.
Kamai T, Tsujii T, Arai K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003; 9: 2632-2641.
26.
Abe H, Kamai T, Tsujii T, et al. Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 2008; 29: 155-161.
27.
Akagi EM, Lavorato-Rocha AM, Maia B de M, et al. ROCK1 as a novel prognostic marker in vulvar cancer. BMC Cancer 2014; 14: 822.
28.
Wu YJ, Tang Y, Li ZF, et al. Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma. Asia Pac J Clin Oncol 2014; 10: e33-e39.
29.
Xue F, Takahara T, Yata Y, et al. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008; 38: 810-817.
30.
Jeong KJ, Park SY, Cho KH, et al. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene 2012; 31: 4279-4289.
31.
Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho- associated kinase signaling prevents breastcancer metastasis to human bone. Cancer Res 2009; 69: 8742-8751.
32.
Patel RA, Forinash KD, Pireddu R, et al. RKI- 1447 is a potent inhibitor of the Rho associatedROCK kinases with anti-invasive and antitumoractivities in breast cancer. Cancer Res 2012; 72: 5025-5034.
33.
Bottinoa J, Gelaleti GB, Maschioa LB, et al. Immuno expression of ROCK-1 and MMP-9 as prognostic markers in breast cancer. Acta Histochemica 2014; 116: 1367-1373.
34.
Dong QZ, Wang Y, Dong XJ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18: 857-865.
35.
Wang JX, Zhou YN, Zou SJ, et al. Correlations of P21 activated kinase 1 expression to clinicopathological features of gastric carcinoma and patients prognosis. Chin J Cancer 2010; 29: 649-654.
36.
Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092-5100.
37.
Niemelä M, Kauko O, Sihto H, et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012; 31: 4266-4278.
38.
Yu G, Liu G, Dong J, Jin Y. Clinical implications of CIP2A protein expression in breast cancer. Med Oncol 2013; 30: 524.
39.
Liu H, Qiu H, Song Y, et al. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. Oncogene 2017; 36: 1952-1964.
40.
Li S, Feng TT, Guo Y, et al. Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy. Oncol Lett 2016; 12: 5370-5376.
41.
Gilkes DM, Xiang L, Lee SJ, et al. Hypoxia-inducible factors mediate coordinated RhoAROCK1expression and signaling in breast cancer cells. Proc Natl Acad Sci U S A 2014; 111: E384-E393.
42.
Lane J, Martin TA, Watkins G, et al. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 2008; 33: 585-593.
43.
Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of Rho-Associated Kinase Signaling Prevents Breast Cancer Metastasis to Human Bone. Cancer Res 2009; 69: 8742-8751.
44.
Borin TF, Arbab AS, Gelaleti GB, et al. Melatonin decreases breast cancer metastasis by modulating ROCK-1 expression. J Pineal Res 2016; 60: 3-15.
45.
Ahmed S, Harb OA, Nawar N. Prognostic Implications of Claudin 4 and Rock 1 in Triple Negative Breast Cancer. J Cancer Treat Res 2017; 5: 95-103.
46.
Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 2006; 26: 4612-4627.
47.
Zhang C, Zhang S, Zhang Z, et al. ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene 2014; 33: 5582-5591.
48.
Huang Q, Qin S, Yuan X, et al. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. Oncol Rep 2017; 38: 598-606.
49.
Tseng L, Liu C, Chang K, et al. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012; 14: R68.
50.
Wei L, Surma M, Shi S, et al. Novel Insights into the Roles of Rho Kinase in Cancer. Arch Immunol Ther Exp (Warsz) 2016; 64: 259-278.
51.
Matsubara M, Bissell MJ. Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D context. Oncotarget 2016; 7: 31602-31622.
52.
Chang F, Zhang Y, Mi J, et al. ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells. Cancer Sci 2018; 109: 3428-3437.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
